Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:02:51.765Z.
Consensus retrieved: 2026-10-06T14:40:51.209Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:02:51.765Z.
Quote observation: 2026-10-06T19:00:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5a9e17458a879267a616e624bc5dc95fe16f3f590d16343b45edf8fcc71148c1
Forward PE Ratio (N/A) = Dated Quote Price ($1.05) / Consensus Forward EPS ($-0.26)
FORWARD PE RATIO
N/A
Ocugen, Inc.
Market Cap
$357.76M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Ocugen, Inc. (OCGN) | $357.76M | N/A |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $357.88M | N/A |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $358.14M | 36.39 |
| Embecta Corp. (EMBC)vs › | $357.32M | 3.42 |
| Viemed Healthcare, Inc. (VMD)vs › | $357.26M | 22.69 |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $357.08M | N/A |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $353.41M | N/A |
| Turn Therapeutics Inc. (TTRX)vs › | $352.39M | N/A |
| Opus Genetics, Inc. (IRD)vs › | $366.25M | N/A |
| Relmada Therapeutics, Inc. (RLMD)vs › | $348.23M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.05, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.26 | $-0.28 – $-0.22 | 4 | n/m |
| 2027-12-31 | $-0.27 | $-0.35 – $-0.19 | 3 | n/m |
| 2028-12-31 | $-0.03 | $-0.39 – $0.55 | 4 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
